Lannett has announced plans to consolidate its research and development operations with the loss of around 10% of its workforce, partly in response to Amneal’s impending launch of a generic competitor to Lannett’s most valuable individual product, fluphenazine hydrochloride tablets.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?